Ferring announced that the Food and Drug Administration (FDA) has approved the name changes of its newly acquired products to be marketed as Zomacton (somatropin [rDNA origin]; formerly Tev-Tropin) for injection, and the needle-free delivery system as Zoma-Jet (formerly Tjet). Ferring acquired Tev-Tropin and Tjet from Teva in December 2014.
Zomacton is indicated for the treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone. It stimulates linear growth in children who lack adequate levels of endogenous growth hormone. Treatment of growth hormone-deficient children with somatropin produces increased growth rates and IGF-1 concentrations that are similar to those seen after therapy with human growth hormone of pituitary origin.
Zomacton is anticipated to launch in the second quarter of 2015 in 5mg and 10mg strengths, with the 10mg dose in a pre-filled syringe. The Zoma-Jet needle-free device is anticipated to launch in 5mg and 10mg strengths later in 2015.
For more information call (888) 337-7464 or visit FerringUSA.com.
This article originally appeared on MPR